ENDRA Life Sciences Inc. (NDRA) stock
NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
$4.04+0.12 (+2.93%)
Close on Nov 18, 2026Market cap $6.05MP/E –Yield –
ENDRA Life Sciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
ENDRA Life Sciences's free cash flow for the twelve months ending Dec 31, 2025 was -$5.20M. For fiscal 2025 it was -$5.20M. The highest annual figure on record is -$3.31M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.20M | – |
| FY2024 | Dec 31, 2024 | -$7.42M | – |
| FY2023 | Dec 31, 2023 | -$9.58M | – |
| FY2022 | Dec 31, 2022 | -$12.97M | – |
| FY2021 | Dec 31, 2021 | -$11.17M | – |
| FY2020 | Dec 31, 2020 | -$10.82M | – |
| FY2019 | Dec 31, 2019 | -$8.63M | – |
| FY2018 | Dec 31, 2018 | -$7.80M | – |
| FY2017 | Dec 31, 2017 | -$3.31M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$1.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.16M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.17M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.18M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.60M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.27M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.19M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.75M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.80M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.14M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.12M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.45M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.11M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.95M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.48M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.66M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.55M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.90M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.57M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.88M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.45M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.38M | – |
| Q3 FY2017 | Sep 30, 2017 | -$546.61K | – |
See a number that looks wrong?